Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib + ICP-248 vs Orelabrutinib in R/R MZL
NCT07896590Phase 3Not yet recruiting
- Sponsor
- InnoCare Pharma
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 3 trial of mesutoclax in marginal zone lymphoma (MZL), sponsored by InnoCare Pharma. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
mesutoclax
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07896590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07896590.